Phase II sbir heliosafe-2: a platform for the fast, label-free, automated evaluation of sterility
Ended Definitive Contract Awarded Last action
- Contract number
- HR001122C0146
- Awardee
-
Heliowave Technologies Inc. UEI F9T3KRMMEXM4
- Awarding agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Obligated
- $1,749,858
Award facts
- Opportunity
-
- Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Pre-Solicitation · HR001120S0019 · Posted Feb 12, 2020
- Contract value 100% obligated
- $1,749,858.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- College Station, TX, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $500,000 | |
| Supplemental Agreement for work within scope | $705,878 | |
| Other Administrative Action | $0 | |
| Original award | $543,980 |
About this award
This is a $1,749,858.00 firm fixed price SBIR Phase II contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Heliowave Technologies LLC, a self-certified small disadvantaged business based in College Station, Texas. The contract supports the development of the HELIOSAFE-2 platform, a system for fast, label-free, automated evaluation of sterility, which aligns with DARPA's mission focus on chemical and biological defense capabilities. This award builds on a previous $225,000 SBIR Phase I contract received by Heliowave in 2021 to begin development of the HELIOSAFE technology. The current Phase II effort will advance the platform through August 2025. Heliowave has also received a $466,950 research grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop the Heliowave Quant system, an integrated platform leveraging droplet microfluidics and impedance detection for bioburden assessment.
Quick answers
Who was awarded contract HR001122C0146?
HR001122C0146 was awarded to Heliowave Technologies Inc. by Defense Advanced Research Projects Agency (Department of Defense) on August 22, 2022.
How much is contract HR001122C0146 worth?
The government has obligated $1,749,858 on HR001122C0146.
Was contract HR001122C0146 competed?
The extent of competition for HR001122C0146 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award